The Effect of Valproic Acid and Levetiracetam on Bone Metabolism in Children with Epilepsy | ||||
| Zagazig University Medical Journal | ||||
| Article 50, Volume 31, Issue 1.1, January 2025, Page 446-453 PDF (733.16 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2023.195766.2755 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ereny Samir Labib Awad  ; Mohamed Elsayed Amer
| ||||
| Department of Pediatrics, Faculty of Medicine, Zagazig University, Egypt | ||||
| Abstract | ||||
| Background: Epilepsy is not an uncommon neurological condition among Egyptian children. Early diagnosis of bone metabolism abnormalities in epileptic children using biochemical markers could be a valuable issue. One of these markers is the total serum vitamin D level which can provide a novel insight into the pathogenesis of the bone metabolism disorders. Aim: To explore the function of total serum vitamin D in children with epilepsy receiving valproic acid or levetiracetam or both and to correlate lowered level with development of bone metabolism disorders. Patients and methods: This case-control study was conducted at Zagazig University's paediatric neurology and endocrinology centre and paediatric outpatient clinic Hospitals on 70 children. Patients were divided into control Group: included 35 children with epilepsy as a control group and case group: included 35 children with epilepsy subdivided into 3 subgroups according to the type of treatment: BI: 10 patients received Navalporate, BII: 10 patients received levatiracetam and BIII: 15 patients received both of Navalporate+ levatiracetam. All patients were subjected to laboratory and Z ray investigations. Results: There is statistically significance compared to the other investigated groups, the case group had significantly lower levels of vitamin D. Statistically, there is a significant difference between the studied groups concerning osteopenia changes which was significantly higher in case group (40%) than control group (0%). There is no statistically significant difference between the treatment groups osteopenia changes. Conclusion: Antiepileptic medicines had a deleterious impact on bone health, with no discernible differences between LEV and VPA. | ||||
| Keywords | ||||
| Valproic Acid; Levetiracetam; Bone Metabolism; Epilepsy | ||||
|
Statistics Article View: 5,785 PDF Download: 125 |
||||
